Quick Answer
China SXT Pharmaceuticals, Inc. reported Long-Term Debt of $96.3 thousand for fiscal year 2025.
China SXT Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $96.3K | -17.8% |
| 2024 | $117.1K | -0.6% |
| 2023 | $117.9K | +1773.2% |
| 2021 | $6.3K | -82.8% |
| 2020 | $36.5K | -12.5% |
| 2019 | $41.7K | — |
- China SXT Pharmaceuticals, Inc. showed a decrease of -17.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2025 period, China SXT Pharmaceuticals, Inc.’s long-term debt has grown by 130.8% (from $41.7 thousand to $96.3 thousand).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: